Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics: $3.79B Nasdaq biopharma focused on groundbreaking immune‑mediated therapies, strong R&D investment, and a resilient market trajectory.

Arcutis Biotherapeutics Inc. has reported a 164% year-over-year increase in net product revenue, driven by the success of its flagship product ZORYVE and a growing pipeline, positioning the company for growth in the immune-mediated diseases market.

Arcutis Biotherapeutics is making significant progress in the treatment of atopic dermatitis, with its ZORYVE cream showing promising results in pediatric patients and the company poised for growth and commercialization.